Crohn's disease and peptic ulcer disease: A personal comparative analysis

2021 ◽  
Vol 1 (2) ◽  
Author(s):  
◽  

Until the Hruska Postulate and its intellectual fulfillment [1-7], Crohn's disease was a disease entity without either cure or validation. The explanation put forward for its pathogenesis is that the body's immune system selectively turned against something within the gastrointestinal tract. That disruption of the immune system's pro-inflammatory Th1 response could produce evidence of mucosal healing and temporary abatement of disease was aggressively pushed as documentation of the concepts validity. Crohn's disease became the linchpin for 193 journals, 86 conferences and 15,631 articles about or related to autoimmunity. When sought for antibodies to a specific target organ could be demonstrated in a number of diseases. In congenital rubella, the presence of anti-islet cell antibodies introduced the hypothesis that autoimmunity was responsible for the higher incidence of abnormal glucose tolerance tests observed [9]. An equally plausible explanation was that the documented viral replication within islet cells of the pancreas sufficiently altered cellular structure so as to create cross-reacting antibodies. Most claims of autoimmunity have been based upon the demonstration of an antibody that cross-reacts with a cell or subunit within the target organ.

Author(s):  
Vítor Macedo Silva ◽  
Marta Freitas ◽  
Pedro Boal Carvalho ◽  
Francisca Dias de Castro ◽  
Tiago Cúrdia Gonçalves ◽  
...  

2020 ◽  
Vol 26 (Supplement_1) ◽  
pp. S75-S75
Author(s):  
Scott D Lee ◽  
Anand Singla ◽  
Caitlin Kerwin ◽  
Kindra Clark-Snustad

Abstract Background Vedolizumab (VDZ) is an effective treatment for Crohn’s disease (CD); however, inadequate and loss of response is common. Pivotal VDZ trials evaluated alternative dosing intervals, demonstrating numeric but not statistical superiority in efficacy as compared to FDA-approved dosing. The safety and effectiveness of FDA-approved and modified-dosing schedules in a real-world population are unknown. We aimed to evaluate clinical and endoscopic effectiveness & safety of standard and modified maintenance VDZ dosing in a real world cohort. Methods We retrospectively reviewed CD patients (pts) treated with >3 months VDZ, assessing Harvey Bradshaw Index (HBI), Simple Endoscopic Score for Crohn’s disease (SESCD), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), C-reactive protein (CRP), albumin and hematocrit prior to and following standard VDZ dosing, and prior to and following modified VDZ maintenance dosing. We measured duration on therapy and adverse events. Results We identified 226 eligible pts, mean age 41.5 years, 55.3% female, median disease duration 10 years, 88.9% with prior biologic exposure. Mean duration on VDZ was 28.3 months. Standard VDZ dosing: 61.5% of pts with active clinical disease and adequate follow up data achieved clinical response after 3–12 months; 41.0% had clinical remission. 51.9% of pts with active endoscopic disease and adequate follow up data achieved mucosal improvement; 42.3% had endoscopic remission; 26.0% had mucosal healing after 3–24 months. 50.0% of pts with elevated CRP and adequate follow up data normalized CRP after 3–12 months. Modified maintenance dosing: 72 non-remitters to standard VDZ dosing received modified VDZ maintenance dosing. 51.5% of pts with active clinical disease prior to starting dose modification and adequate follow up data achieved clinical response after 3–12 months of modified maintenance dosing; 42.4% had clinical remission. 22.2% of pts with SESCD ≥3 prior to starting dose modification achieved mucosal improvement after 3–24 months; 22.2% had mucosal healing. 26.7% of pts with SESCD ≥4 prior to starting modified dosing had endoscopic remission after 3–24 months. 50.0% of pts with elevated CRP and adequate follow up data normalized their CRP after 3–12 months. Safety: 82.7% of pts reported ≥1 adverse events, most commonly infection and worsening CD symptoms. Discussion Standard VDZ dosing resulted in clinical and endoscopic improvement in pts with moderate-severe CD, with prior exposure to multiple advanced therapies. For non-remitters to standard dosing, modified VDZ maintenance dosing improved clinical disease activity in ∼50% of pts and improved endoscopic disease activity in ∼20% of pts, suggesting that for pts who did not achieve remission with standard VDZ dosing, modified VDZ dosing may result in clinical and endoscopic improvement.


2010 ◽  
Vol 138 (5) ◽  
pp. S-85-S-86 ◽  
Author(s):  
Jill P. Smith ◽  
Sandra I. Bingaman ◽  
Francesca Ruggiero ◽  
David T. Mauger ◽  
Aparna Mukherjee ◽  
...  

Science ◽  
2021 ◽  
Vol 371 (6534) ◽  
pp. 1154-1159 ◽  
Author(s):  
Umang Jain ◽  
Aaron M. Ver Heul ◽  
Shanshan Xiong ◽  
Martin H. Gregory ◽  
Elora G. Demers ◽  
...  

Alterations of the mycobiota composition associated with Crohn’s disease (CD) are challenging to link to defining elements of pathophysiology, such as poor injury repair. Using culture-dependent and -independent methods, we discovered that Debaryomyces hansenii preferentially localized to and was abundant within incompletely healed intestinal wounds of mice and inflamed mucosal tissues of CD human subjects. D. hansenii cultures from injured mice and inflamed CD tissues impaired colonic healing when introduced into injured conventionally raised or gnotobiotic mice. We reisolated D. hansenii from injured areas of these mice, fulfilling Koch’s postulates. Mechanistically, D. hansenii impaired mucosal healing through the myeloid cell–specific type 1 interferon–CCL5 axis. Taken together, we have identified a fungus that inhabits inflamed CD tissue and can lead to dysregulated mucosal healing.


Sign in / Sign up

Export Citation Format

Share Document